Market Research Industry Reports

Neuroendocrine Tumors - Pipeline Review, H2 2017

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Neuroendocrine Tumors - Pipeline Review, H2 2017

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Neuroendocrine Tumors - Pipeline Review, H2 2017, provides an overview of the Neuroendocrine Tumors (Oncology) pipeline landscape.

Neuroendocrine tumor begins in the hormone-producing cells of the bodys neuroendocrine system, which is made up of cells that are a cross between traditional endocrine cells (or hormone-producing cells) and nerve cells. Symptom includes hyperglycemia, diarrhea, loss of appetite/weight loss, thickening or lump in any part of the body, jaundice, headache, anxiety and gastric ulcer disease. Treatments include surgery, radiation therapy and chemotherapy.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Neuroendocrine Tumors - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Neuroendocrine Tumors (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neuroendocrine Tumors (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Neuroendocrine Tumors and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 2, 29, 25, 2, 6, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 2 and 2 molecules, respectively.

Neuroendocrine Tumors (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Neuroendocrine Tumors (Oncology).
- The pipeline guide reviews pipeline therapeutics for Neuroendocrine Tumors (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Neuroendocrine Tumors (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Neuroendocrine Tumors (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Neuroendocrine Tumors (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Neuroendocrine Tumors (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Neuroendocrine Tumors (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
Introduction 5
Neuroendocrine Tumors - Overview 6
Neuroendocrine Tumors - Therapeutics Development 7
Neuroendocrine Tumors - Therapeutics Assessment 18
Neuroendocrine Tumors - Companies Involved in Therapeutics Development 30
Neuroendocrine Tumors - Drug Profiles 52
Neuroendocrine Tumors - Dormant Projects 444
Neuroendocrine Tumors - Discontinued Products 446
Neuroendocrine Tumors - Product Development Milestones 447
Appendix 458

List Of Tables


Number of Products under Development for Neuroendocrine Tumors, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Neuroendocrine Tumors - Pipeline by 2X Oncology Inc, H2 2017
Neuroendocrine Tumors - Pipeline by AbbVie Inc, H2 2017
Neuroendocrine Tumors - Pipeline by Advanced Accelerator Applications SA, H2 2017
Neuroendocrine Tumors - Pipeline by Aegis Therapeutics LLC, H2 2017
Neuroendocrine Tumors - Pipeline by Amgen Inc, H2 2017
Neuroendocrine Tumors - Pipeline by Aquestive Therapeutics, H2 2017
Neuroendocrine Tumors - Pipeline by AstraZeneca Plc, H2 2017
Neuroendocrine Tumors - Pipeline by AVEO Pharmaceuticals Inc, H2 2017
Neuroendocrine Tumors - Pipeline by Boehringer Ingelheim GmbH, H2 2017
Neuroendocrine Tumors - Pipeline by Celgene Corp, H2 2017
Neuroendocrine Tumors - Pipeline by Cielo Therapeutics Inc, H2 2017
Neuroendocrine Tumors - Pipeline by Cleave Biosciences Inc, H2 2017
Neuroendocrine Tumors - Pipeline by Crinetics Pharmaceuticals Inc, H2 2017
Neuroendocrine Tumors - Pipeline by Daiichi Sankyo Co Ltd, H2 2017
Neuroendocrine Tumors - Pipeline by Dauntless Pharmaceuticals Inc, H2 2017
Neuroendocrine Tumors - Pipeline by DexTech Medical AB, H2 2017
Neuroendocrine Tumors - Pipeline by Eli Lilly and Co, H2 2017
Neuroendocrine Tumors - Pipeline by Esperance Pharmaceuticals Inc, H2 2017
Neuroendocrine Tumors - Pipeline by Exelixis Inc, H2 2017
Neuroendocrine Tumors - Pipeline by Foresee Pharmaceuticals Co Ltd, H2 2017
Neuroendocrine Tumors - Pipeline by Fujifilm Holdings Corporation, H2 2017
Neuroendocrine Tumors - Pipeline by Hutchison MediPharma Ltd, H2 2017
Neuroendocrine Tumors - Pipeline by Ignyta Inc, H2 2017
Neuroendocrine Tumors - Pipeline by Ipsen SA, H2 2017
Neuroendocrine Tumors - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2017
Neuroendocrine Tumors - Pipeline by Karyopharm Therapeutics Inc, H2 2017
Neuroendocrine Tumors - Pipeline by Madrigal Pharmaceuticals Inc., H2 2017
Neuroendocrine Tumors - Pipeline by Mateon Therapeutics Inc, H2 2017
Neuroendocrine Tumors - Pipeline by Merck & Co Inc, H2 2017
Neuroendocrine Tumors - Pipeline by Merck KGaA, H2 2017
Neuroendocrine Tumors - Pipeline by Midatech Pharma Plc, H2 2017
Neuroendocrine Tumors - Pipeline by Millennium Pharmaceuticals Inc, H2 2017
Neuroendocrine Tumors - Pipeline by Molecular Templates Inc, H2 2017
Neuroendocrine Tumors - Pipeline by MolMed SpA, H2 2017
Neuroendocrine Tumors - Pipeline by Novartis AG, H2 2017
Neuroendocrine Tumors - Pipeline by Peptron Inc, H2 2017
Neuroendocrine Tumors - Pipeline by Pfizer Inc, H2 2017
Neuroendocrine Tumors - Pipeline by Pharma Mar SA, H2 2017
Neuroendocrine Tumors - Pipeline by Progenics Pharmaceuticals Inc, H2 2017
Neuroendocrine Tumors - Pipeline by Provectus Biopharmaceuticals Inc, H2 2017
Neuroendocrine Tumors - Pipeline by Regulaxis SAS, H2 2017
Neuroendocrine Tumors - Pipeline by Strongbridge Biopharma plc, H2 2017
Neuroendocrine Tumors - Pipeline by Taiwan Liposome Company Ltd, H2 2017
Neuroendocrine Tumors - Pipeline by Tarveda Therapeutics Inc, H2 2017
Neuroendocrine Tumors - Pipeline by Valeant Pharmaceuticals International Inc, H2 2017
Neuroendocrine Tumors - Pipeline by Vascular Biogenics Ltd, H2 2017
Neuroendocrine Tumors - Pipeline by Xencor Inc, H2 2017
Neuroendocrine Tumors - Dormant Projects, H2 2017
Neuroendocrine Tumors - Dormant Projects, H2 2017 (Contd..1), H2 2017
Neuroendocrine Tumors - Discontinued Products, H2 2017

List Of Figures


Number of Products under Development for Neuroendocrine Tumors, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Top 10 Routes of Administration, H2 2017
Number of Products by Stage and Top 10 Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

Asia-Pacific Neuroendocrine Carcinoma Drugs Market Report 2018

In this report, the Asia-Pacific Neuroendocrine Carcinoma Drugs market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025,

USD 4000View Report

Global Neuroendocrine Carcinoma Drugs Market Professional Survey Report 2018

This report studies Neuroendocrine Carcinoma Drugs in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions,

USD 3500View Report

Neuroendocrine Tumors - Pipeline Review, H1 2017

Neuroendocrine Tumors - Pipeline Review, H1 2017Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Neuroendocrine Tumors - Pipeline Review, H1 2017, provides an overview of the Neuroendocrine Tumors

USD 2000View Report

Neuroendocrine Tumors - Pipeline Review, H2 2016

Neuroendocrine Tumors - Pipeline Review, H2 2016Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Neuroendocrine Tumors Pipeline Review, H2 2016, provides an overview of the Neuroendocrine Tumors

USD 2000View Report

Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 2000
  • Site Licence    USD 4000
  • Enterprise Wide Licence    USD 6000
$ 2000

Reports Details

Published Date : Dec 2017
No. of Pages :467
Country :Global
Category :Pharmaceuticals and Healthcare
Publisher :Global Markets Direct
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube